Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
Self-citationLees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Signals from the lysosome: a control centre for cellular clearance and energy metabolism
Settembre, C., Fraldi, A., Medina, D. L., & Ballabio, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3565 · Cited by 1,697
Inflammation and immune dysfunction in Parkinson disease
Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00684-6 · Cited by 1,382
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
“) and the identification of mutations in the lysosomal glucocerebrosidase gene in individuals with Parkinson diseas”
BackgroundEpidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
“To date (2010), 11 genes and an additional 3 genetic loci have been associated with PD [168–184]; two additional loci await to be confirmed [185, 186].”
BackgroundParkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
“001) in Ashkenazi Jewish patients (152).”
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Gene prioritization through genomic data fusion
Aerts, S., Lambrechts, D., Maity, S., Van Loo, P., Coessens, B., De Smet, F., Tranchevent, L.-C., De Moor, B., Marynen, P., Hassan, B., et al. (2006) · Nature Biotechnology · doi:10.1038/nbt1203 · Cited by 890
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
“…from the inherited deficiency of the lysosomal enzyme glucocerebrosidase, exhibit clinical parkinsonism and -synuclein-immunoreactive Lewy bodies (Aharon-Peretz et al., 2004); (2) patients with PD have an increased prevalence of mutations in the lysosomal glucocerebrosidase gene (AharonPeretz et…”
BackgroundA Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease
Zimprich, A., Benet-Pagès, A., Struhal, W., Graf, E., Eck, S. H., Offman, M. N., Haubenberger, D., Spielberger, S., Schulte, E. C., Lichtner, P., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.008 · Cited by 816
“168 The American Journal of Human Genetics 89, 168–175, July 15, 2 for Gaucher [MIM 230800] disease, thus implicating a lysosomal enzyme in the pathogenesis of PD.(14,15) Genomewide association studies revealed several low-risk susceptibility loci, among them LAMP3 [MIM 605883] and HIP1R [MIM 605613], which have been…”
BackgroundInfluentialParkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801
The Lysosome as a Regulatory Hub
Perera, R. M., & Zoncu, R. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-111315-125125 · Cited by 660
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696
“Whilst most studies focused on the more common pathogenic mutations in GBA, such as N370S and L444P (Aharon-Peretz et al., 2004; Clark et al., 2005; Sato et al., 2005; Mata et al., 2008; Gan-Or et al., 2008), some smaller studies also performed a complete sequencing screen of the entire GBA gene…”
BackgroundInfluentialWhat Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 611
Phenotype, diagnosis, and treatment of Gaucher's disease
Grabowski, G. A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61522-6 · Cited by 634
The link between the GBA gene and parkinsonism
Sidransky, E., & Lopez, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70190-4 · Cited by 583
“23 Since these initial studies, the frequency of mutations in GBA has been assessed in di ff erent Parkinson’s disease centres worldwide.”
BackgroundGlucocerebrosidase deficiency in substantia nigra of parkinson disease brains
Gegg, M. E., Burke, D., Heales, S. J. R., Cooper, J. M., Hardy, J., Wood, N. W., & Schapira, A. H. V. (2012) · Annals of Neurology · doi:10.1002/ana.23614 · Cited by 564
“Typical parkinsonism is among the neurological complications of GD (including type 1).(3,4) The”
BackgroundDo, C. B., Tung, J. Y., Dorfman, E., Kiefer, A. K., Drabant, E. M., Francke, U., Mountain, J. L., Goldman, S. M., Tanner, C. M., Langston, J. W., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002141 · Cited by 515
“Recently, mutations in GBA have also been identified in PD [36], pointing to a possible functional link between the newly identified candidate gene SCARB2 and PD.”
BackgroundShults, C. W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509567103 · Cited by 476
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies
Nalls, M. A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I. G., Chinnery, P. F., Morris, C. M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1925 · Cited by 439
“71) [2] 2.”
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of Management
Massano, J., & Bhatia, K. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008870 · Cited by 422
“Heterozygous carriers, who do not have GD, are at higher risk of developing sporadic PD or DLB (Aharon-Peretz et al. 2004; Clarket al. 2009; Sidransky et al. 2009).”
BackgroundInfluentialGenetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance
Hernandez, D. G., Reed, X., & Singleton, A. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13593 · Cited by 448
“A year later Aharon-Peretz and colleagues were able to show that inheritance of a single mutation in GBA increased the risk for PD (Aharon-Peretz et al. 2004).”
BackgroundExcessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
“Follow-up studies in large, case-control samples confirmed that heterozygous GBA variants confer at least a 5-fold increased risk of Parkinson’s disease (Aharon-Peretz et al., 2004; Sidransky et al., 2009).”
BackgroundLysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
Dehay, B., Ramirez, A., Martinez-Vicente, M., Perier, C., Canron, M.-H., Doudnikoff, E., Vital, A., Vila, M., Klein, C., & Bezard, E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112368109 · Cited by 379
“The identification of ATP13A2 as a component of LBs raises the possibility that LBs, whose mechanisms of formation and significance for the disease process remain unclear, may seed around lysosomes or undegraded ALs and grow in size by the continuous deposition of undegraded AVs as the disease progresses (11).”
BackgroundInfluentialGlucocerebrosidase activity in Parkinson’s disease with and without GBA mutations
Alcalay, R. N., Levy, O. A., Waters, C. H., Fahn, S., Ford, B., Kuo, S.-H., Mazzoni, P., Pauciulo, M. W., Nichols, W. C., Gan-Or, Z., et al. (2015) · Brain · doi:10.1093/brain/awv179 · Cited by 392
“, 2009), and in carriers of a single GBA mutation (i.e. GBA heterozygotes; Aharon-Peretz et al., 2004; Lwin et al., 2004; Halperin et al., 2006; Goker-Alpan et al., 2008; Bras et al., 2009; Kalinderi et al., 2009; Mitsui et al., 2009; Sidransky et al., 2009; Giraldo et al., 2011).”
BackgroundThe genetics of Parkinson's disease: Progress and therapeutic implications
Singleton, A. B., Farrer, M. J., & Bonifati, V. (2013) · Movement Disorders · doi:10.1002/mds.25249 · Cited by 354
“This was followed by the observation that carriers of a single GBA mutation appeared to be at a much higher risk for PD.(49) Despite the strong initial association, it took many years to build a convincing argument for single GBA mutations as a risk factor for typical PD.”
BackgroundDifferential effects of severe vs mild GBA mutations on Parkinson disease
Gan-Or, Z., Amshalom, I., Kilarski, L. L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N., & Orr-Urtreger, A. (2015) · Neurology · doi:10.1212/wnl.0000000000001315 · Cited by 364
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset
Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A., & Orr-Urtreger, A. (2008) · Neurology · doi:10.1212/01.wnl.0000304039.11891.29 · Cited by 360
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…et al. 2006b; Yu et al. 2003), it is also of interest that there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
BackgroundThe two-century journey of Parkinson disease research
Przedborski, S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.25 · Cited by 345
Incidence of Parkinson disease in North America
Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., on behalf of the Parkinson’s Foundation P4 Group, et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00410-y · Cited by 341
“Potential reasons for the lower risk in Asians include lower prevalence of pathogenic genetic risk factors (e.g., LRRK2 or GBA mutations), differential exposure to risk, or resilience to PD-like neurodegeneration due to lifestyle or diet 44,45 .”
Lysosomal impairment in Parkinson's disease
Dehay, B., Martinez‐Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., & Bezard, E. (2013) · Movement Disorders · doi:10.1002/mds.25462 · Cited by 340
“Conversely, patients with GD, although clinically different from PD, not infrequently exhibit parkinsonism, a-synuclein–immunoreactive LBs, and loss of melanized dopaminergic neurons.(41,43) Intralysosomal accumulation of glucosylceramide has been proposed as the most likely pathogenic mechanism linked to GBA loss-of-…”
BackgroundSphingolipids: membrane microdomains in brain development, function and neurological diseases
Olsen, A. S. B., & Færgeman, N. J. (2017) · Open Biology · doi:10.1098/rsob.170069 · Cited by 311
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease
Di Fonzo, A., Chien, H. F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G., Fabbrini, G., Marconi, R., Fincati, E., Abbruzzese, G., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000260963.08711.08 · Cited by 339
Genetics of the neuronal ceroid lipofuscinoses (Batten disease)
Mole, S. E., & Cotman, S. L. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.011 · Cited by 331
“The age-at-onset and neuropathology of FTLD-TDP and NCL are markedly different and exemplify genetic links that have been emerging between rare diseases and common neurological disorders, such as Niemann-Pick C disease with Alzheimer’s disease [11] and type 1 Gaucher disease with Parkinson’s disease [12]; (3) Evidence…”
BackgroundThe genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. B. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 316
Sardi, S. P., Clarke, J., Kinnecom, C., Tamsett, T. J., Li, L., Stanek, L. M., Passini, M. A., Grabowski, G. A., Schlossmacher, M. G., Sidman, R. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108197108 · Cited by 319
Cullen, V., Sardi, S. P., Ng, J., Xu, Y., Sun, Y., Tomlinson, J. J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22400 · Cited by 303
Glucocerebrosidase and its relevance to Parkinson disease
Do, J., McKinney, C., Sharma, P., & Sidransky, E. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0336-2 · Cited by 300
Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps
Levy, O. A., Malagelada, C., & Greene, L. A. (2009) · Apoptosis · doi:10.1007/s10495-008-0309-3 · Cited by 287
“Epidemiological studies suggest that heterozygous carriers of GBA mutations are at increased risk of PD [86, 87].”
Molecular pathogenesis of Parkinson disease: insights from genetic studies
Gasser, T. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001148 · Cited by 290
Lesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C., Viallet, F., Lohmann, E., Corvol, J.-C., Honoré, A., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq454 · Cited by 287
Gaucher disease: pathological mechanisms and modern management
Jmoudiak, M., & Futerman, A. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05351.x · Cited by 288
“Recently, a clinical association has been reported between the presence of mutations in the GlcCerase gene and Parkinsonism (Aharon-Peretz et al, 2004; Lwin et al, 2004).”
BackgroundGBA Variants and Parkinson Disease: Mechanisms and Treatments
Smith, L., & Schapira, A. H. V. (2022) · Cells · doi:10.3390/cells11081261 · Cited by 256
“Considering that GBA mutation carriers are as likely to develop PD as homozygotes even though they retain more activity [43,84,100], and that most GD patients do not develop PD [83] even though GCase activity is very low, it seems likely that loss of activity is not solely responsible for PD onset.”
BackgroundBrockmann, K., Srulijes, K., Pflederer, S., Hauser, A., Schulte, C., Maetzler, W., Gasser, T., & Berg, D. (2015) · Movement Disorders · doi:10.1002/mds.26071 · Cited by 267
“VC 2014 International Parkinson and Movement Disorder Society Key Words: dementia with Lewy bodies, lower urinary tract dysfunction, autonomic failure, sphincter motor unit potential, Parkinson’s disease Dementia with Lewy bodies (DLB) is characterized by various combinations of dementia and parkinsonism, and visual h…”
BackgroundInfluentialGBA-associated PD presents with nonmotor characteristics
Brockmann, K., Srulijes, K., Hauser, A.-K., Schulte, C., Csoti, I., Gasser, T., & Berg, D. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ab77 · Cited by 268
MUTATIONS IN GBA ARE ASSOCIATED WITH FAMILIAL PARKINSON DISEASE SUSCEPTIBILITY AND AGE AT ONSET
Sidransky, E., Samaddar, T., & Tayebi, N. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b28601 · Cited by 259
Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease
Gan-Or, Z., Dion, P. A., & Rouleau, G. A. (2015) · Autophagy · doi:10.1080/15548627.2015.1067364 · Cited by 260
Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease
Clark, L. N., Ross, B. M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000276989.17578.02 · Cited by 252
Sardi, S. P., Clarke, J., Viel, C., Chan, M., Tamsett, T. J., Treleaven, C. M., Bu, J., Sweet, L., Passini, M. A., Dodge, J. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220464110 · Cited by 251
Parkinson’s disease: proteinopathy or lipidopathy?
Fanning, S., Selkoe, D., & Dettmer, U. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-019-0103-7 · Cited by 236
The relationship between glucocerebrosidase mutations and Parkinson disease
Migdalska‐Richards, A., & Schapira, A. H. V. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13385 · Cited by 231
“• A subset of PD-GBA1 patients is identified with null GBA1 alleles, such as 84GG and IVS2+1G>A, which do not encode GCase (Aharon-Peretz et al. 2004; Gan-Or et al. 2008; Clark et al. 2009).”
BackgroundMagalhaes, J., Gegg, M. E., Migdalska-Richards, A., Doherty, M. K., Whitfield, P. D., & Schapira, A. H. V. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw185 · Cited by 234
Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers
Anheim, M., Elbaz, A., Lesage, S., Durr, A., Condroyer, C., Viallet, F., Pollak, P., Bonaïti, B., Bonaïti-Pellié, C., & Brice, A. (2012) · Neurology · doi:10.1212/wnl.0b013e318245f476 · Cited by 238
Shared dysregulated pathways lead to Parkinson's disease and diabetes
Santiago, J. A., & Potashkin, J. A. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.01.002 · Cited by 227
The rapidly evolving view of lysosomal storage diseases
Parenti, G., Medina, D. L., & Ballabio, A. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202012836 · Cited by 230
“Alpha-synuclein accumulation has been found in several LSDs (Settembre et al, 2008a; Shachar et al, 2011; Di Malta et al, 2012) and suggests a link between alpha-synuclein aggregation toxicity and neurodegeneration in LSDs. Extensive work has been done about beta-glucocerebrosidase deficiency as a risk factor for the…”
BackgroundGlucocerebrosidase mutations are an important risk factor for Lewy body disorders
Goker-Alpan, O., Giasson, B. I., Eblan, M. J., Nguyen, J., Hurtig, H. I., Lee, V. M.-Y., Trojanowski, J. Q., & Sidransky, E. (2006) · Neurology · doi:10.1212/01.wnl.0000230215.41296.18 · Cited by 230
“of cases (% of n) 1 M:0 F (4) 17 M:10 F (96) 8 M:0 F (23) 15 M:12 F (77) 0 7 M:5 F (100)”
Glucocerebrosidase and Parkinson disease: Recent advances
Schapira, A. H. V. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.03.013 · Cited by 219
“This relationship was first identified in the Ashkenazi Jewish population and began to attract attention after a number of reports (Aharon-Peretz et al., 2004; Tayebi et al., 2001).”
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease
Halliday, G. M., Ophof, A., Broe, M., Jensen, P. H., Kettle, E., Fedorow, H., Cartwright, M. I., Griffiths, F. M., Shepherd, C. E., & Double, K. L. (2005) · Brain · doi:10.1093/brain/awh584 · Cited by 219
“, 2003), in the identification of mutations in the glucocerebrosidase gene (Aharon-Peretz et al., 2004) and with new therapeutics targeting various lipids showing long-term beneficial effects (Beal and Shults, 2003; Muller et al.”
BackgroundComparison of Parkinson Risk in Ashkenazi Jewish Patients With Gaucher Disease and GBA Heterozygotes
Alcalay, R. N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W. K., Pauciulo, M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.313 · Cited by 217
The risk of Parkinson's disease in type 1 Gaucher disease
Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G., & Mistry, P. K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9055-0 · Cited by 223
“Nevertheless, these early observations led to a seminal study that revealed that patients with idiopathic PD had a higher risk of harboring GBA1 mutations compared to the general population (Aharon-Peretz et al. 2004).”
ResultMutations for Gaucher Disease Confer High Susceptibility to Parkinson Disease
Mitsui, J., Mizuta, I., Toyoda, A., Ashida, R., Takahashi, Y., Goto, J., Fukuda, Y., Date, H., Iwata, A., Yamamoto, M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.72 · Cited by 209
“Clinically, patients with PD with heterozygous pathogenic variants in GBA were significantly younger at disease onset than those without such variants, which confirms findings of previous studies.(7,11,12,16,20) To further determine the exact effects of heterozygous GBA variants on PD phenotypes, extensive clinical an…”
ResultMolecular and clinical prodrome of Parkinson disease: implications for treatment
Schapira, A. H. V., & Tolosa, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.52 · Cited by 202
de Araujo, M. E. G., Liebscher, G., Hess, M. W., & Huber, L. A. (2020) · Traffic · doi:10.1111/tra.12714 · Cited by 203
Molecular genetics of Parkinson’s disease: Contributions and global trends
Funayama, M., Nishioka, K., Li, Y., & Hattori, N. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01058-5 · Cited by 189
“Notably, in GD families, many GD-naive GBA1 variant carriers have family members who develop PD [42, 43].”
BackgroundGlucocerebrosidase Gene Mutations: A Risk Factor for Lewy Body Disorders
Mata, I. F., Samii, A., Schneer, S. H., Roberts, J. W., Griffith, A., Leis, B. C., Schellenberg, G. D., Sidransky, E., Bird, T. D., Leverenz, J. B., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.68 · Cited by 207
Association of Glucocerebrosidase Mutations With Dementia With Lewy Bodies
Clark, L. N., Kartsaklis, L. A., Wolf Gilbert, R., Dorado, B., Ross, B. M., Kisselev, S., Verbitsky, M., Mejia-Santana, H., Cote, L. J., Andrews, H., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.54 · Cited by 202
Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning
Dodson, M. W., Zhang, T., Jiang, C., Chen, S., & Guo, M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/ddr573 · Cited by 198
“Interestingly, lysosome dysfunction has been demonstrated in PD patient brains (64,65), and two strong genetic risk factors for PD, mutations in b-glucocerebrosidase (66,67) and ATP13A2 (68), are associated with lysosomal dysfunction, suggesting an important role for lysosome dysfunction in the pathogenesis of PD.”
BackgroundMutations in GBA are associated with familial Parkinson disease susceptibility and age at onset
Nichols, W. C., Pankratz, N., Marek, D. K., Pauciulo, M. W., Elsaesser, V. E., Halter, C. A., Rudolph, A., Wojcieszek, J., Pfeiffer, R. F., & Foroud, T. (2009) · Neurology · doi:10.1212/01.wnl.0000327823.81237.d1 · Cited by 202
The Spectrum of Parkinsonian Manifestations Associated With Glucocerebrosidase Mutations
Goker-Alpan, O., Lopez, G., Vithayathil, J., Davis, J., Hallett, M., & Sidransky, E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.10.1353 · Cited by 199
“3%.(7) An increase in GBA mutations subsequently was demonstrated in patients of different ethnicities with PD.”
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 194
Ysselstein, D., Nguyen, M., Young, T. J., Severino, A., Schwake, M., Merchant, K., & Krainc, D. (2019) · Nature Communications · doi:10.1038/s41467-019-13413-w · Cited by 186
Genetics of Parkinsonʼs disease
Gasser, T. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000170951.08924.3d · Cited by 192
Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
Goker-Alpan, O., Stubblefield, B. K., Giasson, B. I., & Sidransky, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0741-7 · Cited by 181
“this finding was confirmed in multiple independent studies in PD cohorts from different ethnicities and a large international collaborative study, including more than 5,000 subjects with PD and the same number of controls, demonstrated that the odds ratio for carrying a GBA mutation was greater than 5, rendering this…”
ResultMeireles, J., & Massano, J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00088 · Cited by 172
“Some years ago, heterozygous GBA mutations have been associated with a higher risk of PD (Aharon-Peretz et al., 2004; Sidransky et al., 2009), and data even suggested that these patients could have an increased risk for cognitive impairment.”
BackgroundHughes-Wilson, W., Palma, A., Schuurman, A., & Simoens, S. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-74 · Cited by 170
Yap, T. L., Gruschus, J. M., Velayati, A., Westbroek, W., Goldin, E., Moaven, N., Sidransky, E., & Lee, J. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.237859 · Cited by 174
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease
Gan-Or, Z., Ozelius, L. J., Bar-Shira, A., Saunders-Pullman, R., Mirelman, A., Kornreich, R., Gana-Weisz, M., Raymond, D., Rozenkrantz, L., Deik, A., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f180e · Cited by 175
LRRK2 gene in Parkinson disease: Mutation analysis and case control association study
Paisán-Ruíz, C., Lang, A. E., Kawarai, T., Sato, C., Salehi-Rad, S., Fisman, G. K., Al-Khairallah, T., St George-Hyslop, P., Singleton, A., & Rogaeva, E. (2005) · Neurology · doi:10.1212/01.wnl.0000167552.79769.b3 · Cited by 178
Gaucher disease: Progress and ongoing challenges
Mistry, P. K., Lopez, G., Schiffmann, R., Barton, N. W., Weinreb, N. J., & Sidransky, E. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.11.006 · Cited by 165
“However, in this small study they had regional cerebral blood flow pattern deficits similar to those seen in patients with Dementia with Lewy Bodies thatmay correlatewith the reported increased likelihood of cognitive dysfunction reported by patients and found in the literature [83].”
BackgroundInfluentialNagata, M., Izumi, Y., Ishikawa, E., Kiyotake, R., Doi, R., Iwai, S., Omahdi, Z., Yamaji, T., Miyamoto, T., Bamba, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618133114 · Cited by 172
“In addition to Gaucher disease, GBA1 mutation is genetically correlated with Parkinson’s disease (72).”
BackgroundGenetic basis of Parkinson's disease: inheritance, penetrance, and expression
Gasser, T. (2011) · The Application of Clinical Genetics · doi:10.2147/tacg.s11639 · Cited by 157
microRNA Profiles in Parkinson's Disease Prefrontal Cortex
Hoss, A. G., Labadorf, A., Beach, T. G., Latourelle, J. C., & Myers, R. H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00036 · Cited by 168
“Glucocerebrosidase (GBA) deficiency is associated with PD (Aharon-Peretz et al., 2004).”
BackgroundThe Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease
Aflaki, E., Westbroek, W., & Sidransky, E. (2017) · Neuron · doi:10.1016/j.neuron.2017.01.018 · Cited by 159
“In the same year, a cohort of 148 Ashkenazi Jewish patients with PD from Northern Israel were screened for selected GBA1 mutations with mutations identified in 40 patients (Aharon-Peretz et al., 2004).”
Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
Galper, J., Dean, N. J., Pickford, R., Lewis, S. J. G., Halliday, G. M., Kim, W. S., & Dzamko, N. L. (2022) · Brain · doi:10.1093/brain/awac176 · Cited by 182
An updated review of Parkinson's disease genetics and clinicopathological correlations
Ferreira, M., & Massano, J. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12616 · Cited by 167
Rosenbloom, B., Balwani, M., Bronstein, J. M., Kolodny, E., Sathe, S., Gwosdow, A. R., Taylor, J. S., Cole, J. A., Zimran, A., & Weinreb, N. J. (2011) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2010.10.006 · Cited by 158
Mendelian forms of Parkinson's disease
Gasser, T. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.007 · Cited by 161
“zygous mutations carriers as compared to healthy controls [151].”
BackgroundEndocytic membrane trafficking and neurodegenerative disease
Schreij, A. M. A., Fon, E. A., & McPherson, P. S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2105-x · Cited by 162
Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
Setó‐Salvia, N., Pagonabarraga, J., Houlden, H., Pascual‐Sedano, B., Dols‐Icardo, O., Tucci, A., Paisán‐Ruiz, C., Campolongo, A., Antón‐Aguirre, S., Martín, I., et al. (2012) · Movement Disorders · doi:10.1002/mds.24045 · Cited by 155
“These data agree with previous analyses reporting a lack of Gaucher symptoms in PD patients carrying 2 copies of this allele.(4,11,32) As expected, the most frequent mutations in Spanish patients are N370S and L444P.”
ResultGBA-Associated Parkinson’s Disease and Other Synucleinopathies
Gan‐Or, Z., Liong, C., & Alcalay, R. N. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0860-4 · Cited by 167
Nuber, S., Rajsombath, M., Minakaki, G., Winkler, J., Müller, C. P., Ericsson, M., Caldarone, B., Dettmer, U., & Selkoe, D. J. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.014 · Cited by 144
Chiasserini, D., Paciotti, S., Eusebi, P., Persichetti, E., Tasegian, A., Kurzawa-Akanbi, M., Chinnery, P. F., Morris, C. M., Calabresi, P., Parnetti, L., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0010-2 · Cited by 148
“45) cause Gaucher disease (GD) a rare lysosomal storage disorder, and represent a common risk factor for PD [2-4].”
BackgroundThe Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
Velayati, A., Yu, W. H., & Sidransky, E. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0102-x · Cited by 145
“2004 [21] Ashkenazi Jews N370S, L444P, c.”
InfluentialCooray, R., Gupta, V. B., & Suphioglu, C. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02054-6 · Cited by 161
“The genetic studies describe that the mutations in α-synuclein [5, 6], PINK1 [7], DJ-1 (PARK7) [8, 9], ubiquitin genes such as ubiquitin-C-hydrolase [10, 11], and population-specific gene mutations such as glucocerebrosidase gene in Ashkenazi Jews [12] directly relate to the onset of PD [13].”
BackgroundExploring the link between glucocerebrosidase mutations and parkinsonism
Westbroek, W., Gustafson, A. M., & Sidransky, E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.05.003 · Cited by 145
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.